Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, four have given a buy rating and three have given a strong buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $4.75.
Several research firms recently weighed in on IKT. Wall Street Zen upgraded Inhibikase Therapeutics from a "strong sell" rating to a "sell" rating in a report on Saturday. Weiss Ratings reiterated a "sell (d-)" rating on shares of Inhibikase Therapeutics in a report on Thursday, October 15th. HC Wainwright reiterated a "buy" rating and set a $8.00 target price on shares of Inhibikase Therapeutics in a report on Thursday, November 12th. Finally, Chardan Capital reissued a "neutral" rating and set a $1.50 target price on shares of Inhibikase Therapeutics in a research report on Thursday, November 12th.
View Our Latest Analysis on IKT
Inhibikase Therapeutics Stock Down 4.6%
Shares of NASDAQ IKT opened at $1.45 on Tuesday. The business has a fifty day simple moving average of $1.87 and a two-hundred day simple moving average of $1.93. The firm has a market cap of $203.39 million, a PE ratio of -3.62 and a beta of 0.94. Inhibikase Therapeutics has a twelve month low of $1.40 and a twelve month high of $2.61.
Inhibikase Therapeutics (NASDAQ:IKT - Get Free Report) last issued its earnings results on Tuesday, November 10th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.01. On average, research analysts expect that Inhibikase Therapeutics will post -0.41 earnings per share for the current year.
Institutional Investors Weigh In On Inhibikase Therapeutics
Several hedge funds have recently modified their holdings of the business. Soleus Capital Management L.P. increased its holdings in Inhibikase Therapeutics by 3.2% during the third quarter. Soleus Capital Management L.P. now owns 11,225,000 shares of the company's stock valued at $23,067,000 after buying an additional 350,000 shares during the period. Kalehua Capital Management LLC raised its stake in Inhibikase Therapeutics by 118.4% in the first quarter. Kalehua Capital Management LLC now owns 3,821,890 shares of the company's stock worth $6,421,000 after buying an additional 2,071,890 shares in the last quarter. SummitTX Capital L.P. bought a new position in Inhibikase Therapeutics in the first quarter worth approximately $2,561,000. Ally Bridge Group NY LLC bought a new position in Inhibikase Therapeutics in the first quarter worth approximately $2,226,000. Finally, Seven Fleet Capital Management LP lifted its holdings in Inhibikase Therapeutics by 6.5% during the second quarter. Seven Fleet Capital Management LP now owns 346,900 shares of the company's stock worth $704,000 after buying an additional 21,300 shares during the period. Hedge funds and other institutional investors own 3.81% of the company's stock.
About Inhibikase Therapeutics
(
Get Free Report)
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for Parkinson's disease and other neurodegenerative disorders. The company's research centers on small-molecule inhibitors of Abelson tyrosine kinase, or c-Abl, a protein it is investigating for its role in neurodegeneration. Its pipeline has included IKT-148009, an oral c-Abl inhibitor being developed for Parkinson's disease. Inhibikase is based in Atlanta, Georgia, and conducts research and development in the pharmaceutical biotechnology sector.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Inhibikase Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibikase Therapeutics wasn't on the list.
While Inhibikase Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.